Post-marketing reports in FAERS: liver injury with novel oral anticoagulants


Researchers at University of Bologna ( Italy ) have assessed the hepatic safety of Novel Oral AntiCoagulants ( NOACs ) analyzing the publicly available US-FDA Adverse Event Reporting System ( FAERS ).

Reports of Drug-Induced Liver Injury ( DILI ) associated with novel oral anticoagulants were extracted, including Acute Liver Failure ( ALF ) events.

DILI reports represented 3.7% ( N = 146 ) and 1.7% ( N = 222 ) of all reports for Rivaroxaban ( Xarelto ) and Dabigatran ( Pradaxa ), respectively.

No statistically significant association was found for Dabigatran, in primary and secondary analyses.

Disproportionality signals emerged for Rivaroxaban in primary analysis ( acute liver failure: N = 25; reporting odds ratios, ROR = 2.08; 95% CI = 1.34-3.08 ).

In a large proportion of drug-induced liver injury reports concomitant hepatotoxic and/or interacting drugs were recorded: 42% and 37% ( Rivaroxaban and Dabigatran, respectively ), especially statins, Paracetamol ( Acetaminophen ) and Amiodarone.

Among acute liver failure reports, fatal outcome occurred in 49% of cases ( 44% and 51%, Rivaroxaban and Dabigatran, respectively ), whereas rapid onset of the event ( less than 1 week ) was detected in 46% of patients ( 47% and 44% respectively ).

In conclusion, the disproportionality signal for Rivaroxaban calls for further comparative population-based studies to characterize and quantify the actual drug-induced liver injury risk of novel oral anticoagulants, taking into account drug- and patient-related risk factors.
As drug-induced liver injury is unpredictable, these findings strengthen the role of (a) pharmacovigilance to timely detect post-marketing signals of drug-induced liver injury through FAERS and other data sources, (b) clinicians to early assess, on a case-by-case basis, the potential responsibility of novel oral anticoagulants when they diagnose a liver injury. ( Xagena )

Raschi E et al, Br J Clin Pharmacol 2015; Epub ahead of print

XagenaMedicine_2015



Indietro

Altri articoli

Available pharmacological options for rhythm control strategy in atrial fibrillation are limited by sub-optimal efficacy and potentially serious adverse events....


Randomized controlled trials ( RCTs ) regarding use of Ranolazine for the prevention and cardioversion of atrial fibrillation have yielded...


Catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy can be challenging because of the complexity of underlying...


The clinical efficacy and toxicity of Amiodarone ( Cordarone ) may be determined more effectively by tissue deposition than by...


Although there are many different antiarrhythmic drugs approved for rhythm management of atrial fibrillation, little comparative effectiveness data exist to...


Amiodarone ( Cordarone ) is known to affect the thyroid, but little is known about thyroid recovery after short-term Amiodarone...


Sotalol ( Sotalex ) and Amiodarone ( Cordarone ) are commonly prescribed antiarrhythmics for the treatment of post-operative atrial fibrillation...


Ibutilide ( Corvert ) is a rapid-acting antiarrhythmic drug with worldwide use for conversion of recent-onset atrial fibrillation. Vernakalant (...


The 2015 Guidelines for Resuscitation recommend Amiodarone ( Cordarone ) as the antiarrhythmic drug of choice in the treatment of...


The European Commission has granted marketing authorization for Epclusa ( Sofosbuvir 400 mg / Velpatasvir 100 mg ), the first...